131 related articles for article (PubMed ID: 36014415)
1. In Silico and In Vitro Studies of
Suručić R; Radović Selgrad J; Kundaković-Vasović T; Lazović B; Travar M; Suručić L; Škrbić R
Molecules; 2022 Aug; 27(16):. PubMed ID: 36014415
[TBL] [Abstract][Full Text] [Related]
2. Alchemilla viridiflora Rothm.: the potent natural inhibitor of angiotensin I-converting enzyme.
Radović J; Suručić R; Niketić M; Kundaković-Vasović T
Mol Cell Biochem; 2022 Jul; 477(7):1893-1903. PubMed ID: 35348979
[TBL] [Abstract][Full Text] [Related]
3. Potential inhibitor for blocking binding between ACE2 and SARS-CoV-2 spike protein with mutations.
Tsai MS; Shih WT; Yang YH; Lin YS; Chang GH; Hsu CM; Yeh RA; Shu LH; Cheng YC; Liu HT; Wu YH; Wu YH; Shen RC; Wu CY
Biomed Pharmacother; 2022 May; 149():112802. PubMed ID: 35279013
[TBL] [Abstract][Full Text] [Related]
4. Uncovering the impact of SARS-CoV2 spike protein variants on human receptors: A molecular dynamics docking and simulation approach.
Zaheer M; Ali N; Javed H; Munir R; Jamil N
J Infect Public Health; 2023 Oct; 16(10):1544-1555. PubMed ID: 37566991
[TBL] [Abstract][Full Text] [Related]
5. Molecular screening of glycyrrhizin-based inhibitors against ACE2 host receptor of SARS-CoV-2.
Ahmad S; Waheed Y; Abro A; Abbasi SW; Ismail S
J Mol Model; 2021 Jun; 27(7):206. PubMed ID: 34169390
[TBL] [Abstract][Full Text] [Related]
6. Selection of Bis-Indolyl Pyridines and Triphenylamines as New Inhibitors of SARS-CoV-2 Cellular Entry by Modulating the Spike Protein/ACE2 Interfaces.
Lapaillerie D; Charlier C; Guyonnet-Dupérat V; Murigneux E; Fernandes HS; Martins FG; Magalhães RP; Vieira TF; Richetta C; Subra F; Lebourgeois S; Charpentier C; Descamps D; Visseaux B; Weigel P; Favereaux A; Beauvineau C; Buron F; Teulade-Fichou MP; Routier S; Gallois-Montbrun S; Meertens L; Delelis O; Sousa SF; Parissi V
Antimicrob Agents Chemother; 2022 Aug; 66(8):e0008322. PubMed ID: 35861550
[TBL] [Abstract][Full Text] [Related]
7. Corilagin and 1,3,6-Tri-
Binette V; Côté S; Haddad M; Nguyen PT; Bélanger S; Bourgault S; Ramassamy C; Gaudreault R; Mousseau N
Phys Chem Chem Phys; 2021 Jul; 23(27):14873-14888. PubMed ID: 34223589
[TBL] [Abstract][Full Text] [Related]
8. Identification of SARS-CoV-2 Cell Entry Inhibitors by Drug Repurposing Using
Choudhary S; Malik YS; Tomar S
Front Immunol; 2020; 11():1664. PubMed ID: 32754161
[TBL] [Abstract][Full Text] [Related]
9. A molecular docking study revealed that synthetic peptides induced conformational changes in the structure of SARS-CoV-2 spike glycoprotein, disrupting the interaction with human ACE2 receptor.
Souza PFN; Lopes FES; Amaral JL; Freitas CDT; Oliveira JTA
Int J Biol Macromol; 2020 Dec; 164():66-76. PubMed ID: 32693122
[TBL] [Abstract][Full Text] [Related]
10. Withanone from
Balkrishna A; Pokhrel S; Singh H; Joshi M; Mulay VP; Haldar S; Varshney A
Drug Des Devel Ther; 2021; 15():1111-1133. PubMed ID: 33737804
[TBL] [Abstract][Full Text] [Related]
11. Enhanced Binding of SARS-CoV-2 Spike Protein to Receptor by Distal Polybasic Cleavage Sites.
Qiao B; Olvera de la Cruz M
ACS Nano; 2020 Aug; 14(8):10616-10623. PubMed ID: 32806067
[TBL] [Abstract][Full Text] [Related]
12. Pomegranate peel extract polyphenols attenuate the SARS-CoV-2 S-glycoprotein binding ability to ACE2 Receptor: In silico and in vitro studies.
Suručić R; Travar M; Petković M; Tubić B; Stojiljković MP; Grabež M; Šavikin K; Zdunić G; Škrbić R
Bioorg Chem; 2021 Sep; 114():105145. PubMed ID: 34246969
[TBL] [Abstract][Full Text] [Related]
13. Broad and Differential Animal Angiotensin-Converting Enzyme 2 Receptor Usage by SARS-CoV-2.
Zhao X; Chen D; Szabla R; Zheng M; Li G; Du P; Zheng S; Li X; Song C; Li R; Guo JT; Junop M; Zeng H; Lin H
J Virol; 2020 Aug; 94(18):. PubMed ID: 32661139
[TBL] [Abstract][Full Text] [Related]
14. Modeling SARS-CoV-2 spike/ACE2 protein-protein interactions for predicting the binding affinity of new spike variants for ACE2, and novel ACE2 structurally related human protein targets, for COVID-19 handling in the 3PM context.
Tragni V; Preziusi F; Laera L; Onofrio A; Mercurio I; Todisco S; Volpicella M; De Grassi A; Pierri CL
EPMA J; 2022 Mar; 13(1):149-175. PubMed ID: 35013687
[TBL] [Abstract][Full Text] [Related]
15. Coevolution, Dynamics and Allostery Conspire in Shaping Cooperative Binding and Signal Transmission of the SARS-CoV-2 Spike Protein with Human Angiotensin-Converting Enzyme 2.
Verkhivker G
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33158276
[TBL] [Abstract][Full Text] [Related]
16. Scaffold morphing of arbidol (umifenovir) in search of multi-targeting therapy halting the interaction of SARS-CoV-2 with ACE2 and other proteases involved in COVID-19.
Choudhary S; Silakari O
Virus Res; 2020 Nov; 289():198146. PubMed ID: 32866534
[TBL] [Abstract][Full Text] [Related]
17. Molecular docking study of potential phytochemicals and their effects on the complex of SARS-CoV2 spike protein and human ACE2.
Basu A; Sarkar A; Maulik U
Sci Rep; 2020 Oct; 10(1):17699. PubMed ID: 33077836
[TBL] [Abstract][Full Text] [Related]
18. Multidisciplinary Approaches Identify Compounds that Bind to Human ACE2 or SARS-CoV-2 Spike Protein as Candidates to Block SARS-CoV-2-ACE2 Receptor Interactions.
Day CJ; Bailly B; Guillon P; Dirr L; Jen FE; Spillings BL; Mak J; von Itzstein M; Haselhorst T; Jennings MP
mBio; 2021 Mar; 12(2):. PubMed ID: 33785634
[TBL] [Abstract][Full Text] [Related]
19. Computational Alanine Scanning and Structural Analysis of the SARS-CoV-2 Spike Protein/Angiotensin-Converting Enzyme 2 Complex.
Laurini E; Marson D; Aulic S; Fermeglia M; Pricl S
ACS Nano; 2020 Sep; 14(9):11821-11830. PubMed ID: 32833435
[TBL] [Abstract][Full Text] [Related]
20. Potential antiviral activity of isorhamnetin against SARS-CoV-2 spike pseudotyped virus in vitro.
Zhan Y; Ta W; Tang W; Hua R; Wang J; Wang C; Lu W
Drug Dev Res; 2021 Dec; 82(8):1124-1130. PubMed ID: 33847382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
